Trial Profile
A Placebo-controlled, Double-blind, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients With Severe Sepsis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-TNF-alpha polyclonal antibody (Primary)
- Indications Septic shock
- Focus Adverse reactions
- Sponsors AstraZeneca
- 06 Jun 2014 New trial record